A Novel Adjustable Tandem and Ring Applicator for Improved Dosimetry in Cervical Cancer HDR Brachytherapy.

Technol Cancer Res Treat · 2026 · PMC13305905 · PMID 42332958

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significancep = 0.06so close (0.05 < p ≤ 0.1)

The novel RTA showed mean daily dose reductions of 0.33 Gy for bladder (p = 0.04), 0.34 Gy for rectum (p = 0.06, borderline significance), and 0.67 Gy for sigmoid colon (p = 0.01), with no significant change in CTV coverage (p = 0.55).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.